Dyadic International, Inc. has entered into a License and Development Agreement with Proliant Biologicals, LLC, trading as Proliant Health and Biologicals. The agreement details include an initial payment of $500,000 from Proliant to Dyadic, with a second payment of the same amount upon the transfer of a Production Strain and a final payment also of $500,000 upon achieving a specific productivity level. Additionally, Dyadic is entitled to a share of the profits from Proliant's sales of animal-free recombinant serum albumin products produced using Dyadic's technology. On June 28, a press release related to the Agreement was issued.